ATLANTA, GA – – (ACCESSWIRE – November 7, 2022) – – Holzer & Holzer, LLC is investigating whether Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) complied with federal securities laws. On October 31, 2022, Instil Bio announced a pause in enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 due to “a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured.” Following this announcement, the Company’s stock price dropped.
If you purchased Instil Bio stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/instil-bio/ to discuss your legal rights.